Global Dialysis Market Report Forecast By Type (Peritoneal Dialysis, Hemodialysis), Product & Services (Services, Equipment, Consumables, Drugs), End User (Home Dialysis, In Center Dialysis), Countries and Company Analysis 2024-2032

Dialysis Market Analysis

The Global Dialysis Market will reach US$ 164.44 Billion by 2032, up from US$ 111.75 Billion in 2023, with a CAGR of 4.39% between 2024 and 2032. Some of the factors driving the market are the growing number of kidney transplant patients requiring post-operative dialysis, the expanding availability of reimbursement policies for dialysis treatments, and the growing emphasis on early diagnosis and intervention for renal illnesses.

Dialysis Industry Overview

Dialysis is a common treatment for people with chronic renal failure. It removes waste products from the blood, such as urea and creatinine, caused by defective kidney function. This procedure is used to treat both kidney transplantation and end-stage renal disease (ESRD). The blood is cleansed, extra fluid and toxins are eliminated, and electrolyte balance is restored during the process.

Hemodialysis and peritoneal dialysis are the two forms of dialysis. During hemodialysis, waste products like urea are removed extracorporeally from the patient's blood. Peritoneal dialysis uses the peritoneum, which is located in the abdomen, for dialysis. Market expansion is being aided by the rise in end-stage renal disease (ESRD) patients, the number of patients with diabetes and hypertension, and the finance for the development of new medications. Moreover, dialysis is preferred to kidney transplantation, which is expected to fuel additional market expansion for dialysis. Furthermore, rising healthcare costs, a growing senior population, and rising disposable income are probably going to drive market growth.

Growth Drivers of Dialysis Market

Increasing Propensity for Chronic Kidney Diseases to Support Market Expansion

ESRD and CKD collectively account for one of the greatest costs of healthcare. One of the main drivers of this market's growth is the rising prevalence of chronic kidney illnesses and renal failure, as well as the growing comorbidity of diabetes and hypertension in patients. When a patient reaches end-stage renal disease (ESRD), either a kidney transplant or long-term renal infusion therapy is required to keep one or both kidneys functionally intact. As a result, the increasing incidence of ESRD is contributing to the increased expense burden of kidney disorders worldwide and is a major driver of the revenue growth of major industry participants.

For example, in September 2021, some 786,000 Americans had End-Stage Renal Disease (ESRD), of which 71% were receiving dialysis, according to data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKD). Similarly, almost 4.8 million people worldwide had chronic renal failure in 2022, according to Fresenius Medical Care's 2022 annual report. It is anticipated that this figure will rise by 3-6% year.

Moreover, new items and consumables are being introduced with permission from regulatory bodies. As the number of dialysis patients rises, industry participants are concentrating on introducing cutting-edge goods to meet shifting consumer needs. For example, Victor Gura received a patent for a wearable artificial kidney from the US Patent Office in May 2021. This apparatus is a dialysis machine on a smaller scale.

Kidney problems are a result of growing lifestyle modifications.

The market is being stimulated by the increasing trend of lifestyle modifications. The growth of renal difficulties can be attributed to modern lives marked by sedentary routines, poor eating habits, and elevated levels of stress. Kidney illnesses are primarily caused by chronic ailments like diabetes and hypertension, which can be brought on by unhealthy diets heavy in processed foods, high in salt, and insufficient hydration. The prevalence of chronic renal disorders has increased as a result of the link between lifestyle variables and kidney difficulties. The need for dialysis treatments has surged as a result of the growth in kidney-related problems, since those who are affected need renal replacement therapy to preserve their quality of life. The need to provide more dialysis services due to the growing patient pool propels the dialysis market's expansion. Because of this, producers of medical equipment, researchers, and healthcare practitioners are driven to create novel approaches and plans of action in order to meet the increasing demand for dialysis treatments.

North America Dialysis Market

North America accounted for a substantial share of the market in 2023. It is projected that the region will maintain its dominant position in the market for the duration of the forecast. The main factors anticipated to propel the expansion of the regional market during the projection period are the increasing treatment rates and elevated incidence of end-stage renal disease (ESRD) and chronic kidney disease (CKD) in the United States and Canada. The growth in coronavirus infections, which can occasionally result in renal failure, is expected to increase the need for dialysis services and supplies in the US. For example, in September 2021, the National Institutes of Health (NIH) in the United States published a report stating that 1 in 7 adults in the nation, or roughly 786,000 people, had end-stage renal disease.

In addition, government initiatives, reimbursement policies, and awareness campaigns that support early diagnosis and treatment of kidney-related issues all contribute to a rise in the usage of dialysis treatments. Moreover, the concentration of leading dialysis companies and medical research institutes in North America facilitates the development and uptake of state-of-the-art dialysis systems.

Dialysis Company Analysis

Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, DaVita Inc., Fresenius Medical Care AG & Co. KGaA, JMS Co. Ltd., and Medtronic Plc are the major companies in the dialysis market.

Dialysis Company News

In April 2024, DaVita Inc. was able to raise a sizeable sum of money to grow its home dialysis program around the country. By offering cutting-edge home dialysis equipment and support services, the funding seeks to enhance accessibility and enhance patient results.

In January 2024, in order to increase its footprint in emerging areas, Fresenius Medical Care announced the acquisition of a local dialysis provider in Latin America. It is anticipated that Fresenius' service capabilities and reach in the region will be improved by this calculated approach.

In October 2023, A strategic cooperation was signed between Dialyze Direct and Northeast Georgia Health Ventures (NGHV) to offer home dialysis services to skilled nursing facilities (SNFs) in Georgia.

In June 2023, Improved filtration technology in a new hemodialysis machine from Medtronic was announced. By improving the effectiveness and safety of dialysis treatments, this product seeks to strengthen Medtronic's leadership in the dialysis industry.

Type - Market breakup in 2 viewpoints:

1. Peritoneal Dialysis

2. Hemodialysis

Product & Services - Market breakup in 4 viewpoints:

1. Services

2. Equipment

3. Consumables

4. Drugs

End User - Market breakup in 2 viewpoints:

1. Home Dialysis

2. In Center Dialysis

Countries - Market breakup in 25 viewpoints:

• North America

United States

Canada

• Europe

France

Germany

Italy

Spain

United Kingdom

Belgium

Netherland

Turkey

• Asia Pacific

China

Japan

India

Australia

South Korea

Thailand

Malaysia

Indonesia

New Zealand

• Latin America

Brazil

Mexico

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

All the key players have been covered from 5 Viewpoints:

• Business Overview
• Key Persons
• Product Portfolio
• Recent Development & Strategies
• Financial Insights

Key Players Analysis:

1. Asahi Kasei Corporation

2. B. Braun Melsungen AG

3. Baxter International Inc.

4. Becton Dickinson and Company

5. DaVita Inc.

6. Fresenius Medical Care AG & Co. KGaA

7. JMS Co. Ltd.

8. Medtronic Plc.